Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (IQV) delivers integrated healthcare insights through its unique combination of clinical research expertise and advanced data analytics. This news hub provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access official press releases and curated news coverage spanning clinical trial milestones, healthcare data partnerships, regulatory updates, and technology innovations. Our collection serves as a strategic resource for understanding IQVIA's role in optimizing drug development cycles and commercial decision-making.
Key content categories include earnings announcements, merger/acquisition activity, leadership changes, and analytical breakthroughs in real-world evidence applications. Bookmark this page for efficient tracking of IQVIA's progress in transforming clinical research through data-driven solutions.
IQVIA Holdings Inc. (NYSE:IQV) plans to raise €1.45 billion (approximately $1.76 billion) through an offering of senior notes due 2026 and 2029. The proceeds will be used to redeem all outstanding 3.250% senior notes due 2025, including premiums, and to cover fees related to the offering. The completion of the notes offering is subject to market and customary conditions. The company emphasizes that this does not constitute an offer to sell or solicit buyers, and the notes will not be registered under the Securities Act of 1933.
IQVIA (NYSE:IQV) reports a significant milestone as 140 life science companies across nearly 90 countries have adopted its Orchestrated Customer Engagement (OCE) solution. This reflects a strong demand for its commercial technology, highlighted by the recent addition of Laboratoires Théa as a client. In 2020, 60 new customers implemented OCE, which includes major pharmaceutical firms like AstraZeneca and Roche. The platform connects customer interactions and internal departments, leveraging AI to improve efficiency and enhance engagement.
IQVIA Holdings reported a strong fourth quarter for 2020, with revenue of $3,298 million, representing a 13.9% increase year-over-year. Technology & Analytics Solutions (TAS) grew 17.4%, while Research & Development Solutions (R&DS) increased 14.5%. However, Contract Sales & Medical Solutions (CSMS) revenue declined by 10%. The R&DS contracted backlog rose 18.5% to $22.6 billion. The company achieved an adjusted EBITDA of $735 million and raised its 2021 financial guidance, projecting revenues between $12,550 million and $12,900 million.
IQVIA Holdings Inc. (NYSE:IQV) will announce its fourth-quarter and full-year 2020 financial results on February 10, 2021, before the market opens. A conference call and webcast will be hosted by the management team at 9:00 a.m. ET on the same day. Interested parties must register in advance for the call. The earnings release and financial information will be available on the IQVIA Investor Relations website. IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services within the life sciences industry, employing around 70,000 people across more than 100 countries.
IQVIA has partnered with Laboratoires Théa, a top independent eye care group in Europe, to implement its Orchestrated Customer Engagement (OCE) platform and the OneKey HCP/HCO reference database in over 22 markets. This collaboration aims to enhance Théa’s digital strategy and customer engagement, especially in the wake of changes prompted by the COVID-19 pandemic. The OCE platform integrates various functions to improve service delivery and relationships with healthcare professionals. IQVIA serves more than 125 life sciences companies with its innovative solutions.
Q2 Solutions, a clinical trial laboratory services organization formed from an IQVIA and Quest Diagnostics joint venture, has partnered with Adaptive Biotechnologies to provide advanced immune-driven research services. The collaboration introduces immunoSEQ® Assay and immunoSEQ® T-MAP™ COVID, enhancing testing capabilities for pharma clients, particularly in understanding immune responses related to COVID-19 and drug development. This partnership is poised to improve the drug development lifecycle through detailed immune response analytics.
IQVIA (NYSE:IQV) has announced a collaboration with Servier to enhance its R&D clinical development processes through the SCORE program. This initiative aims to transform Servier's clinical trial applications and improve patient outcomes by utilizing optimized processes, data-driven insights, and innovative technology. Over the next two years, IQVIA will implement a robust program that leverages its expertise in R&D consulting, digital transformation, and technology solutions. The partnership is poised to address unmet medical needs and support Servier's ambitious growth plans.
